Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company was founded in 2005 by Jack A. Khattar, who serves as the President and CEO. It was established as a spin-off from Shire Laboratories, the drug delivery subsidiary of Shire plc, where Mr. Khattar had also held the position of President and CEO. His career includes extensive experience in marketing, business development, and corporate strategy at pharmaceutical and drug delivery companies such as Merck & Co., Novartis, and CIMA Labs.

The company's business model is fully integrated, covering research and development, manufacturing, and commercialization. Revenue is primarily generated from product sales, alongside licensing agreements and partnerships. Supernus focuses its marketing and sales efforts within the United States, utilizing its own specialty sales force to target neurologists and psychiatrists. For international markets, the company pursues strategic collaborations with other pharmaceutical firms to license its products. The company's portfolio includes treatments for conditions such as epilepsy, migraine, Parkinson's disease (PD), and attention-deficit hyperactivity disorder (ADHD). Key products include Qelbree, Gocovri, Oxtellar XR, and Trokendi XR. Supernus has expanded its portfolio through strategic acquisitions, including the CNS portfolio of US WorldMeds in 2020 and Sage Therapeutics in 2025, which added ZURZUVAE for postpartum depression.

Supernus is a publicly traded company headquartered in Rockville, Maryland. The company invests significantly in research and development to create new treatments for CNS disorders, with a pipeline that includes candidates for depression and other neurological conditions. It leverages proprietary drug delivery technologies, such as Microtrol, Solutrol, and EnSoTrol, to improve upon existing medications through advanced extended-release formulations.

Keywords: central nervous system, CNS diseases, neurology, psychiatry, pharmaceuticals, drug development, commercialization, epilepsy, Parkinson's disease, ADHD, migraine, drug delivery technologies, extended-release, Qelbree, Gocovri, Oxtellar XR, Trokendi XR, ZURZUVAE, Jack Khattar, specialty pharma, biopharmaceutical